Advertisement
UK markets closed
  • FTSE 100

    8,142.48
    +63.62 (+0.79%)
     
  • FTSE 250

    19,818.77
    +216.79 (+1.11%)
     
  • AIM

    755.61
    +2.49 (+0.33%)
     
  • GBP/EUR

    1.1663
    +0.0007 (+0.06%)
     
  • GBP/USD

    1.2460
    -0.0051 (-0.40%)
     
  • Bitcoin GBP

    50,963.11
    -125.21 (-0.25%)
     
  • CMC Crypto 200

    1,324.36
    -72.18 (-5.17%)
     
  • S&P 500

    5,096.53
    +48.11 (+0.95%)
     
  • DOW

    38,176.77
    +90.97 (+0.24%)
     
  • CRUDE OIL

    83.86
    +0.29 (+0.35%)
     
  • GOLD FUTURES

    2,343.80
    +1.30 (+0.06%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.52
    +244.24 (+1.36%)
     
  • CAC 40

    8,092.84
    +76.19 (+0.95%)
     

China Importing and Exporting Hemp, Cannabis and CBD Regulatory Report 2021: Customs Order No.43 Explicitly Prohibits Cannabis Entry to China

Dublin, Dec. 24, 2021 (GLOBE NEWSWIRE) -- The "Regulatory Report: China - Importing and Exporting Hemp, Cannabis and CBD" report has been added to ResearchAndMarkets.com's offering.

While the Customs Order No.43 explicitly prohibits cannabis entry to China, these substances could still qualify for a narcotic and psychotropic drugs import and export permit. According to the application guidance, the import licence can only be approved for medical and scientific purposes.

Unlike import, export of CBD products is not strictly controlled in China and mainly depends on the rules of the destination country. This report takes a closer look at import and export regulation in China, covering hemp, CBD and cannabis, including full/broad-spectrum extracts, CBD isolate and finished products (food, cosmetics and vaping).

Cannabis, cannabis resin, extracts and tinctures are listed in the Chinese catalogue of narcotic drugs and psychotropic drugs, meaning they cannot be imported for commercial purposes or purchased from overseas by consumers.

Key Topics Covered:

1 Executive summary

2 Cannabis

3 Hemp

4 CBD isolate

5 Full/broad-spectrum extracts

6 Finished products

7 Relevant laws

8 Relevant bodies


For more information about this report visit https://www.researchandmarkets.com/r/7kfcot

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900